The competition between two of the world's largest obesity drugmakers has arrived in court. Novo Nordisk filed suit against Eli Lilly, alleging that Lilly used outdated data in advertising to support the claim that its products were more effective than Wegovy, Novo Nordisk's weight-loss treatment. The Danish company characterizes those advertisements as "deliberately false."
What the complaint says
The accusation is specific: Eli Lilly did not merely shade a comparison but, Novo Nordisk alleges, reached for data it knew was no longer current to make a superiority case against Wegovy. That distinction matters legally. Aggressive comparative advertising is one thing. Choosing stale evidence to construct a superiority claim is a harder position to defend.
Wegovy is central to Novo Nordisk's identity in the obesity market. Any public claim that a rival product is more effective goes directly at that commercial standing.
The counterargument
Eli Lilly can argue that the word "outdated" is doing a lot of heavy lifting in Novo Nordisk's framing. Comparative advertising is common in the pharmaceutical industry, and the line between a claim that is aggressively optimistic and one that crosses into deliberate misrepresentation is contested territory in court. Lilly's likely position is that the data it cited was accurate when the campaign ran, and that its vintage does not make the ads false in any legally meaningful sense.
The line to watch
This lawsuit does not settle which drug actually performs better. That question lives in clinical data, not court filings. The legal question is narrower: whether using older comparative data to assert superiority over Wegovy constitutes deliberate falsehood. If Novo Nordisk prevails, the precedent tightens how quickly pharmaceutical companies must update advertising claims as new evidence emerges. If Lilly prevails, companies retain broader latitude to hold comparative positions even when fresher data exists.
The case also reflects how much the commercial stakes in the obesity drug market have sharpened. Both companies are competing for the same prescribers and the same patients. Wegovy's name appearing in a rival's advertising at all is a measure of how firmly it sits at the center of that fight.